3Siegel R,Ma J,Zou I,et al.Cancer statistics,2014[J].CA Cancer J Clin,2014,64(1):9-29.
4Center MM,Jemai A,Lortet-Tleulent J,et al.International variation in prostate cancer incidence and mortality rates[J].Eur Urol,2012,61(6):1079-1092.
5Huggins C,Hodges CV.Studies on prostatic cancer:I.The effect of castration,of estrogen and of androgen injection on serum phos- phatases in metastatic carcinoma of the prostate.1941[J].J Urol,2002,168(1):9-12.
6Lassi K,Dawson NA.Emerging therapies in castrate-resistant prostate cancer[J].Curr Opin Oncol,2009,21(3):260-265.
7Fine SW.Variants and unusual patterns of prostate cancer:clinico- pathologic and differential diagnostic considerations[J].Adv Anat Pathol,2012,19(4):204-216.
8Epstein Jl,Amin MB,Beltran H,et al.Proposed morphologic classifi- cation of prostate cancer with neuroendocrine differentiation[J].Am J Surg Pathol,2014,38(6):756-767.
10Wang HX Yao YH,Li BG,et al.Neuroendocrine prostate cancer(NEPC)progressing from conventional prostatic adenocarcinoma:factors associated with time to development of NEPC and survival from NEPC diagnosis-a systematic review and pooled analysis[J].J Clin Oncol,2014,32(30):3383-3390.
